What is Circular Genomics?
Circular Genomics operates at the intersection of biotechnology and mental health, specializing in the development of diagnostic tools that utilize circular RNA to improve patient outcomes. Its flagship innovation, MindLight, represents a significant advancement in the field, serving as the first antidepressant response test that employs brain-derived biomarkers to predict patient efficacy for SSRI treatments. By streamlining the clinical decision-making process, the company addresses critical inefficiencies in mental health care, offering a data-driven approach to personalized medicine that promises to reduce the trial-and-error nature of psychiatric prescribing.
How much funding has Circular Genomics raised?
Circular Genomics has raised a total of $28.1M across 4 funding rounds:
Angel/Seed
$4.5M
Series A
$8.3M
Other Financing Round
$250K
Series A
$15M
Angel/Seed (2021): $4.5M, investors not publicly disclosed
Series A (2024): $8.3M led by Mountain Group Partners, Cottonwood Technology Fund, Tramway Venture Partners, and UNM Rainforest Innovations
Other Financing Round (2025): $250K supported by Alzheimer's Drug Discovery Foundation
Series A (2025): $15M featuring Alzheimer's Drug Discovery Foundation, Mountain Group Partners, and Poplar Grove Investments
Key Investors in Circular Genomics
Mountain Group Partners
A Nashville-based venture capital firm specializing in early-stage investments within the Life Sciences and Technology sectors, known for its patient, long-term approach to company building.
Cottonwood Technology Fund
An early-stage venture capital fund focused on patent-based hard science and deep tech startups, providing capital and business development support to drive innovation from research to market.
Alzheimer's Drug Discovery Foundation
A not-for-profit organization dedicated to accelerating the development of drugs for Alzheimer's disease through innovative research funding and strategic partnerships.
What's next for Circular Genomics?
With this major enterprise-level funding, Circular Genomics is poised to accelerate its clinical validation efforts and expand the commercial footprint of its diagnostic suite. The strategic focus will likely shift toward scaling operational capacity and deepening its research pipeline to address a broader spectrum of neurological conditions. As the company transitions from early-stage development to a more mature commercial phase, the integration of its biomarker technology into standard clinical workflows will be the primary catalyst for long-term growth and market penetration in the precision psychiatry sector.
See full Circular Genomics company page
